BLTE
USDBelite Bio Inc American Depositary Shares
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$114.150
Máximo
$114.440
Mínimo
$112.000
Volumen
0.08M
Fundamentos de la Empresa
Capitalización de Mercado
4.0B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
0.07M
Bolsa
NCM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug
Benchmark Maintains Buy on Belite Bio, Raises Price Target to $132
Benchmark analyst Bruce D. Jackson maintains Belite Bio with a Buy and raises the price target from $80 to $132.
Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.